viewPreveCeutical Medical Inc.

PreveCeutical Medical unveils promising findings from non-addictive analgesics program

The firm is developing therapies using organic and nature identical products

The company currently has five research and development programs on the go

Health sciences group PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) said it had completed a study of peptides to develop as non-addictive painkillers, with promising results.

The firm is developing therapies using organic and nature identical products.

READ: PreveCeutical Medical reports converting acid phytocannabinoids to neutral form

One of its programs is for non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone.

Preveceutical said that via a meticulous process it had now identified five novel peptide constructs, which preferentially target the receptor subtype which is of interest to the company and is purported to avoid addictive and tolerance-inducing side effects.

This subset of peptides has demonstrated potency, in a well-accepted functional dose response assay, that is on par with clinically available agents, such as morphine, the company added.

Chief research officer Dr Harendra Parekh told investors: "We are very pleased with this promising development, as a result of numerous iterations between our peptide design and cell-based screening efforts, we have now yielded a number of constructs which discriminate between the key pain receptors in the body, and importantly, avoid activation of those purported to lead to dependence."

Preveceutical shares in Toronto were unchanged at $0.06 each.

Contact Giles at [email protected]

Follow him on Twitter @Gile74

Quick facts: PreveCeutical Medical Inc.

Price: 0.03 CAD

Market: CSE
Market Cap: $11.89 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...



Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 15/11/19

2 min read